Otsuka Ends Partnership With Akebia Over CRL-Related CKD Anemia Drug

May 17, 2022

Otsuka Pharmaceutical said it is ending a collaboration with Akebia Therapeutics over the investigational chronic kidney disease-associated anemia drug vadadustat.

Otsuka said it pulled out of the partnership because Cambridge, Mass.-based Akebia received a Complete Response Letter from the FDA in March regarding the New Drug Application. The FDA said that the data did not support a favorable benefit-risk assessment for vadadustat in dialysis and non-dialysis patients. The agency also flagged safety issues, including the risk of drug-induced liver injury.

The two companies entered into their partnership in December 2016 for the U.S. market and expanded it in April 2017 to include other parts of the world.

View today's stories